搜尋
Alnylam Pharmaceuticals Inc
ALNY添加自選
200.380USD
-86.240-30.09%
交易中 （美東）報價延遲15分鐘
26.53B總市值
49.04本益比TTM
關於 Alnylam Pharmaceuticals Inc 公司
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Alnylam Pharmaceuticals Inc簡介
公司代碼ALNY
公司名稱Alnylam Pharmaceuticals Inc
上市日期May 28, 2004
CEOGreenstreet (Yvonne L)
員工數量2230
證券類型Ordinary Share
年結日May 28
公司地址675 W Kendall St
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02142-1168
電話16175518200
網址https://www.alnylam.com/
公司代碼ALNY
上市日期May 28, 2004
CEOGreenstreet (Yvonne L)
Alnylam Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.31K
+15.58%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
807.00
+83.15%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
671.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
671.00
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.31K
+15.58%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
807.00
+83.15%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
671.00
--
常見問題
Alnylam Pharmaceuticals Inc的前五大股東是誰？
Alnylam Pharmaceuticals Inc的前五大股東如下：Dr. Yvonne L. Greenstreet, M.D.
有多少機構持有Alnylam Pharmaceuticals Inc(ALNY)的股份？
截至2026Q1，共有1634家機構持有Alnylam Pharmaceuticals Inc的股份，合計持有的股份價值約為133.66M，占公司總股份的100.11% 。與2025Q4相比，機構持股有所增加，增幅為-6052832.00。
哪個業務部門對Alnylam Pharmaceuticals Inc的收入貢獻最大？
在2026Q1，AMVUTTRA業務部門對Alnylam Pharmaceuticals Inc的收入貢獻最大，創收2.31B，占總收入的62.30% 。